A multinational research team led by researchers at Institute of Science Tokyo, RIKEN, and the University of Toronto has ...

New Assay Expands INDIGO’s GPCR Portfolio and Supports Development of Next-Generation CNS-Related Therapeutics STATE ...

T cell activation—the process by which these key immune defenders recognize threats and mobilize against them—depends on ...

GLP-1 RAs appear to be associated with lower all-cause mortality for patients living with type 2 diabetes and brain metastases.

The new 12-month project extends a prior two-year award for which Habegger studied mechanisms of glucagon, Glucagon-like peptide-1 (GLP-1), and glucose-dependent insulinotropic polypeptide (GIP) and ...

Plant immunity is largely initiated at the cellular level, with each cell capable of autonomous detection and response, while ...

The findings of this cohort study suggest that glucagon-like peptide–1 receptor agonist (GLP-1 RA) use was associated with significant reduction in all-cause mortality among patients with cancer with ...

Scientists have discovered that T cell receptors activate through a hidden spring-like motion that had never been seen before. This breakthrough may help explain why immunotherapy works for some ...

The dominant paradigm of metabolic treatment has long operated within a narrow frame: reduce caloric intake, increase caloric expenditure, manage the consequences. That framework is now obsolete. The ...

When it comes to brain proteins, small changes can make a dramatic difference. Researchers studying NMDA (N-methyl-D-aspartate) receptors, which are essential for learning, memory and moment-by-moment ...